Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method of pimavanserin key intermediate

A technology of pimavanserin and intermediates, which is applied in the field of synthesis of pharmaceutical molecules, can solve the problems of large impact on operator's health, high DPPA price, unfavorable industrial production, etc., so as to reduce production safety risks and avoid Raney nickel. easy-to-use, easy-to-achieve effects

Active Publication Date: 2018-11-13
LIVZON NEW NORTH RIVER PHARMA
View PDF6 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] Disadvantages of this route: (1) The use of hydrogen to participate in the reaction needs to be carried out under high pressure, and the safety risk is high; the reaction requires a catalyst palladium carbon, which is expensive
(2) Toxic phosgene is involved in the reaction, which has a great impact on the health of the operator, is not conducive to environmental protection, has high safety risks, and is not conducive to industrial production
[0018] The DPPA used in this route is expensive, and the azide compound intermediate will pass through the reaction process, and the generated azide compound has safety hazards such as explosion and high toxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of pimavanserin key intermediate
  • Preparation method of pimavanserin key intermediate
  • Preparation method of pimavanserin key intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Preparation of compound 3 from compound 1

[0068]

[0069] 1) Add p-hydroxybenzaldehyde (14.6g, 122.8mmo1), anhydrous potassium carbonate (25.4g, 184.2mmoL), potassium iodide (1.4g, 12.3mmoL) and 75mL DMF into a 250mL three-necked flask, and heat to 85°C;

[0070] 2) Slowly add chloroisobutane (34.1g, 368.4mmol) to the reaction system, after the addition is complete, the system reacts at 85°C for 6h;

[0071] 3) Stop the reaction, cool the system to room temperature, filter, and rinse the filter cake twice with 90 mL of ethyl acetate;

[0072] 4) Pour the filtrate into 250 mL of water, separate the organic phase, extract the water phase three times with 90 mL of ethyl acetate, combine the organic phases, wash once with 150 mL of saturated brine, dry over anhydrous sodium sulfate, filter, and spin the filtrate to obtain 19.4 g Compound, light yellow liquid, yield 90%.

[0073] MS (m / z): [M+H] + =176.2; The NMR data of compound 3 are as follows: 'H NMR (400MHz, C...

Embodiment 2

[0089] Preparation of compound 3 from compound 1

[0090]

[0091] 1) Add p-hydroxybenzaldehyde (14.6g, 122.8mmo1), anhydrous potassium carbonate (25.4g, 184.2mmoL), potassium iodide (1.4g, 12.3mmoL) and 75mL DMF into a 250mL three-necked flask, and heat to 90°C;

[0092] 2) Slowly add bromoisobutane (50.5g, 368.4mmol) into the reaction system, after the addition is complete, the system reacts at 90°C for 5h;

[0093] 3) Stop the reaction, cool the system to room temperature, filter, and rinse the filter cake twice with 90 mL of ethyl acetate;

[0094] 4) Pour the filtrate into 250 mL of water, separate the organic phase, extract the water phase three times with 90 mL of ethyl acetate, combine the organic phases, wash once with 150 mL of saturated brine, dry over anhydrous sodium sulfate, filter, and spin the filtrate to obtain 19.8 g Compound, light yellow liquid, yield 92%.

[0095] Preparation of compound 4 from compound 3

[0096]

[0097] 5) Add 4-isobutoxybe...

Embodiment 3

[0107] Preparation of compound 3 from compound 1

[0108]

[0109] 1) Add p-hydroxybenzaldehyde (14.6g, 122.8mmo1), anhydrous potassium carbonate (25.4g, 184.2mmoL), potassium iodide (1.4g, 12.3mmoL) and 75mL DMF into a 250mL three-necked flask, and heat to 100°C;

[0110] 2) Slowly add iodoisobutane (67.8g, 368.4mmol) into the reaction system, after the addition is complete, the system reacts at 100°C for 5h;

[0111] 3) Stop the reaction, cool the system to room temperature, filter, and rinse the filter cake twice with 90 mL of ethyl acetate;

[0112] 4) Pour the filtrate into 250 mL of water, separate the organic phase, extract the water phase three times with 90 mL of ethyl acetate, combine the organic phases, wash once with 150 mL of saturated brine, dry over anhydrous sodium sulfate, filter, and spin the filtrate to obtain 19.6 g Compound, light yellow liquid, yield 91%.

[0113] Preparation of compound 4 from compound 3

[0114]

[0115] 5) Add 4-isobutoxyb...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to View More

Abstract

The invention discloses a preparation method of a pimavanserin key intermediate. A synthesis route comprises a process shown in the description. According to the method disclosed by the invention, used raw materials are safe and the cost is low, so that the production cost is effectively reduced. The method disclosed by the invention has moderate reaction conditions and the utilization of phosgenewhich has great toxicity and is not easy to operate can be avoided, so that the method is easy to realize in industry.

Description

technical field [0001] The invention relates to the field of synthesis of medicine molecules, in particular to a synthesis process of medicine molecules, in particular to a method for preparing a pimavanserin intermediate. Background technique [0002] At present, there are about 7 million to 10 million Parkinson's disease patients in the world, and China has 2.6 million people, ranking first in the world, and there will be an increase of 100,000 new patients every year. More than 50% of patients with Parkinson's disease have had psychotic symptoms (PDP). These psychiatric symptoms mainly manifest as hallucinations and delusions, which bring greater challenges to the treatment and care of patients with Parkinson's disease. Parkinson's disease psychosis is a major reason people with Parkinson's disease enter aged care housing. There are currently no approved drugs for Parkinson's disease psychosis other than low-dose clozapine (Clozaril), which has serious safety concerns a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07C265/08C07C263/10C07C253/30C07C255/54C07C213/02C07C217/58
CPCC07C213/02C07C253/30C07C263/10C07C255/54C07C217/58C07C265/08
Inventor 王标陈鑫耀谢伟健彭木荣陈月嫦
Owner LIVZON NEW NORTH RIVER PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com